Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Clene Inc. - Common Stock (NQ: CLNN )

4.400 +0.100 (+2.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment
Via Investor Brand Network
Ancient DNA Suggests Origins of Multiple Sclerosis in EU
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial
Via Investor Brand Network
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
New Study Highlights Role of Mitochondria in Connecting Cancer to Dietary Fat
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials
Via Investor Brand Network
Finnish Study Suggests Exercise Plays Smaller Role in Longevity
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces New Data from HEALEY ALS Platform Trial, Provides Update on ALS Clinical Development Meeting with FDA
Via Investor Brand Network
Exposures Product Safety
Nasdaq Gains 100 Points; CarMax Earnings Top Views
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76.... 
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Refuses Neurology-Focused Clene's Accelerated Approval For Amyotrophic Lateral Sclerosis Treatment, Shares Fall
Clene Inc (NASDAQ: CLNN) provided an amyotrophic lateral sclerosis (ALS) regulatory update from its recent meeting with the FDA to discuss CNM-Au8 for ALS, presenting initial clinical and Neurofilament... 
Via Benzinga
Exposures Product Safety
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Moves Lower; Micron Issues Strong Forecast
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37,296.40 while the NASDAQ rose 0.77% to 14,891.87. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Jumps 250 Points; US Weekly Jobless Claims Edge Higher
U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. Following the market opening Thursday, the Dow traded up 0.72% to 37,348.90 while the NASDAQ rose 0.96%... 
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication Describing Brain Target Engagement in Neurodegenerative Diseases
Via Investor Brand Network
Stem Cell Therapy Shows Promise in Halting Progression of Cognitive Decline in MS Patients
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
Via Investor Brand Network
The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles
Via Investor Brand Network
Study Suggests Parkinson’s Could Be Linked to Onset of Stroke, Heart Disease
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
Via Investor Brand Network
Blood Test Could Detect Worsening MS Symptoms in Patients
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
Via Investor Brand Network
Exposures Product Safety
Australian Study Finds Way to Detect Parkinson’s Prior to Symptom Onset
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.